On this video, Kelly L. Stratton, MD, FACS, presents mre particulars on a part 1B trial evaluating relugolix (Orgovyx) and enzalutamide (Xtandi) for high-risk prostate most cancers. Stratton is an affiliate professor of urologic oncology on the College of Oklahoma, Oklahoma Metropolis.
Transcription:
Sufferers will obtain 6 months of mixed hormonal remedy; once more, that is with relugolix and enzalutamide. After which relying upon whether or not they would favor surgical procedure or radiation to endure native remedy, sufferers have the choice of choosing both radiotherapy or surgical procedure. After which for 18 months after that, they will proceed with mixed hormonal remedy. The overall period of hormonal remedy shall be 2 years. And that actually is essential as a result of we see that there is a profit to mixed hormonal remedy. As an illustration, within the STAMPEDE trial, sufferers underwent 2 years of mixed remedy, those who weren’t metastatic however excessive danger, and it appeared that in that examine, androgen deprivation remedy with abiraterone was useful. We’re additionally awaiting some further research to report, and so we really feel prefer it’s essential to be ready for these research. As an illustration, the PROTEUS examine checked out mixed hormonal remedy and surgical procedure. In that protocol, sufferers acquired 1 12 months of mixed remedy with ADT plus an anti-androgen drug, they usually underwent surgical procedure at 6 months after which continued on for an additional 6 months. So this examine actually bridges the hole between STAMPEDE and PROTEUS and supplies the chance for sufferers to get both surgical procedure or radiation remedy.
This transcription was edited for readability.
